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AIMS : The aim of this study was to evaluate the frequencies of the HLA genotypes DQ2 and DQ8 and the alleles
A1*05, A1*0201, B1*0201 and B1*0302 in individuals with celiac disease in Recife, northeastern Brazil.
METHODS: HLA DQ2 and DQ8 genotyping was performed for 73 individuals with celiac disease and 126 first-degree
relatives with negative transglutaminase serology. The alleles DQA1*05, DQA1*0201, DQB1*02 and DQB1*0302
were identified by sequencing using specific primers and the EU-DQ kit from the Eurospital Laboratory, Trieste, Italy
and double-checked by the All Set SPP kit (Dynal).
RESULTS: Among the 73 cases, 50 (68.5%) had the genotype DQ2, 13 (17.8%) had DQ8, 5 (6.8%) had DQ2 and DQ8,
and 5 did not have any of these genotypes. Among the 5 negative individuals, four had the B1*02 allele and one did
not have any of the alleles studied. B1*02 was the most frequent allele in both groups (94% in the patients and 89%
in the control relatives).
CONCLUSIONS: In this study, celiac disease was associated with the genotypes DQ2 and DQ8. DQ2 predominated,
but the distribution of the frequencies was different from what has been found in European populations and was
closer to what has been found in the Americas. The high frequencies of the HLA genotypes DQ2 and DQ8 that were
found in first-degree relatives would make it difficult to use these HLA genotypes for routine diagnosis of celiac
disease in this group.
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INTRODUCTION
The autoimmune and inflammatory processes that char-
acterize celiac disease are triggered by gluten in genetically
predisposed individuals, in the presence of environmental
aggression that interferes with the integrity of the small
intestine.1 Among the known genetic markers, the HLA
genes have the greatest impact on the development of the
disease.2 The presence of genes coding for DQ2 and DQ8
molecules of the HLA complex class II explains up to 40% of
the occurrence of celiac disease in European populations.3
The association between the genotype DQ2 and celiac is
explained by the high affinity of the DQ2 molecule of HLA
in cells presenting this antigen in the intestinal mucosa,
towards peptides derived from gluten.4
In a multicenter study carried out in Europe, it was
observed that the HLA genotype DQ2 is present in around
86 to 93% of celiac disease patients, while around 3 to 8% of
these patients have DQ8 without DQ2.5 These markers are
also carried by many individuals without celiac disease: 40
to 65% of first-degree relatives of celiac disease patients and
18 to 30% of the general population.6-8 However, in non-
European populations, different frequencies are observed.
In the United States, a greater proportion of HLA DQ8 and a
smaller proportion of DQ2 than in Europe have been
reported. 9 HLA DQ2 and DQ8 frequencies similar to those
observed in the USA have been described in Asian10,
Cuban11 and Chilean12 populations.
Some authors have suggested that the HLA genotypes
DQ2 and DQ8 not only are indicators of genetic vulner-
ability but also may be used for diagnosing celiac disease in
situations that remain undefined even after biopsy.13-14
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Among first-degree relatives, just like among other groups
at risk, active searching for new cases using serological tests
is indicated. These groups present the highest concentration
of cases with undefined diagnoses and would be the great-
est candidates for genotyping. 7,15 However, the frequency
of the HLA genotypes DQ2 and DQ8 among family
members is greater than among the general population
and it also varies between different regions of the world.
Thus, their diagnostic use also varies between populations.
The HLA system is extremely polymorphic and reflects
the process of formation of each population. 16 The Brazilian
population is intensely miscegenated, with marked differ-
ences between the regions. In the northeastern region of
Brazil, the genetic markers for this disease have not been
studied yet. Recent studies have demonstrated that the
frequencies of celiac disease in the Americas and in Brazil
are similar to what has been described in Europe.17-19 This
knowledge has increased the number of new diagnoses of
celiac disease in Brazil, especially among high-risk groups.
The diversity of celiac disease among these groups shows
the need for greater knowledge about celiac disease in this
population. In the present study, we aimed to evaluate the
frequencies of alleles coding for the HLA molecules DQ2
and DQ8 among individuals with celiac disease and their
first-degree relatives in northeastern Brazil.
METHOD
Study population and Design
This study was conducted in pediatric gastroenterology
outpatient clinics in the city of Recife, State of Pernambuco,
northeastern Brazil, between August 2007 and May 2008.
Children and adolescents with a diagnosis of celiac disease
(index cases), together with the first-degree members of
their families (fathers, mothers and siblings) were invited to
participate in this study.
A free and informed consent statement was obtained from
all of the participants in the study. The study had previously
been approved by the Ethics Committee for Research on
Human Beings of the Fernando Figueira Integrated
Medicine Institute (Instituto de Medicina Integral Fernando
Figueira, IMIP), under the number 893, on November 10,
2006, and the work was performed in accordance with the
principles of the 1983 Declaration of Helsinki.
The study had a cross-sectional design, in order to
compare frequencies between cases and family controls.
All the first-degree relatives who agreed to participate in the
study underwent the human tissue transglutaminase (tTG)
serological test, and those with positive findings were
invited to undergo an intestinal biopsy.
Cases were taken to be celiac disease patients with a
diagnosis in accordance with the criteria of ESPGHAN
199020 (index cases) and family members with positive tTG
and signs of villous atrophy on intestinal biopsy. The
control group was formed by first-degree relatives of
patients with negative results from tTG serological tests.
One hundred and eighty-two first-degree relatives of 66
patients were identified during the study period and 161
(88.4%) first-degree relatives were included in the study.
Seven first-degree relatives whose serological tests were
positive and biopsies presented villous atrophy were
included in the case group, while 126 first-degree relatives
with non-reactive serological tests for tTG antibodies made
up the control group.
Serological tests:
After blood sample collection, the blood was centrifuged
and the serum thus obtained was stored in Eppendorf tubes
at -18 C˚. The serum tTG concentration was investigated by
using quantitative ELISA with a commercially available kit
(ImmuLisaTM, IMMCO Diagnostics, Inc, Buffalo, NY, USA).
Values lower than 20 EU/ml were considered negative, as
suggested by the manufacturer.
HLA DQ2 DQ8 genotyping:
Genomic DNAwas extracted from 2 ml of whole blood by
using the Genome Wizard DNA kit (Promega), following
standard protocols. The genotyping was performed by
using the EU-DQ kit from Eurospital (Trieste, Italy). PCR
products were detected by means of electrophoresis, which
was run on 2% agarose gel and viewed under UV light.
HLA haplotypes were double-checked by using the PCR-
SSP Kit AllSet (Dynal, BIOTECH A.S.A, Oslo, Norway).
The frequency of HLA DQ2 and DQ8 were based in the
frequency of the alleles - A1*05, DQB1*02, A1*0201 and
B1*0302 in genotyping. We consider carrier genotype DQ2
individuals who had the alleles A1*05 and DQB1*02 in
genotyping and the genotype DQ8 those who had the allele
B1*0302 in PCR screening.
Statistical analysis:
The frequencies of HLA genotypes and alleles were
described as percentages with their respective confidence
intervals. The continuous variables were described as
medians and percentiles. The frequencies of the groups
were compared by using the chi-squared test (x2). The
significance level adopted was 5% (p,0.05). The data were
stored and analyzed using the EpiInfo 6.04 software
package.
RESULTS
The characteristics of the 73 cases are described in Table 1.
Among the 126 controls, 68 (54%) were women and 58 were
men; 33 (26.2%) were fathers, 45 (35.7%) were mothers and
Table 1 - Sex, age and clinical characteristics of the cases
at the time of diagnosis.
Patients (n = 73)
n %
Sex
Male 37 50,7
Female 36 49,3
Age at diagnosis
Less than 2 years 8 11,0
2 to 6 years 35 47,9
7 to 12 years 17 23,3
13 to 21 years 6 8,2
More than 21 years 7 9,6
Clinical form at diagnosis
Classic form * 29 39,7
Mild gastrointestinal symptoms 21 28,8
Non-gastrointestinal symptoms { 8 11,0
Diagnosis by serological screening { 15 20,5
*Classic form: diarrhea, abdominal distension and associated malnutrition.
{Non-gastrointestinal symptoms in this group: short height, diminished
bone mineral density.
{Indication for serological screening in this group: first-degree relative,
diabetes mellitus. In both groups tTG was utilized for screening.
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48 (38.1%) were siblings. The parents’ ages ranged from 23
to 56 years, with a median of 38 years (P25/75: 33/43 years),
and the siblings’ ages ranged from 20 months to 27 years,
with a median of 13 years (P25/ P75: 8/16 years).
The HLA genotypes DQ2 or DQ8 were present in 68 of the
73 celiac individuals (93.1%; 95% CI: 84 – 97%) and 99 of the
126 controls (78.6%; 95% CI: 70 – 85%). The HLA genotypes
DQ2 and DQ8 frequencies distribution in the two groups
are described in Table 2.
Among the five patients who did not present HLA DQ2
or DQ8, four had the allele B1*02 without A1*05 and one did
not have any of the alleles investigated with the Eu-DQ kit.
The frequencies of the alleles A1*0201, A1*05, B1*02 and
B1*0302 in celiac patient and controls are described in
Table 4. B1*02 was the most frequent allele in both groups
and was found in 93% of the patients and 88 % of the
control. No differences in the distribution of each allele
alone were observed between the two groups.
DISCUSSION
The genotypes DQ2 and DQ8 were present in 93.2% of
patients with Celiac Disease in the Northeast of Brazil. The
HLA DQ2 was present in 75.6% and DQ8 in 17.8% of these
patients and these proportions differ from those described
in European populations.21 In celiac patients of European
population the frequency of the HLA DQ2 is up of 90% e the
HLA DQ8 is between five and 10%, like was described in
recent study performed in 2308 cases from Dutch, UK and
Irish. 22
Differences in the frequencies of the HLA genotypes DQ2
and DQ8 in non-European populations have already been
described. Butterworth et al, in England, demonstrated that
patients of Indian origin had lower frequency of HLA DQ2
than those of British origin.10 Lower frequencies of HLA
DQ2 and higher frequency of HLA DQ8 than European
have also been described among celiac disease patients in
the United States (82% DQ2 and 16% DQ8 only) and in Cuba
(86% DQ2) 11,17
In South America, Araya et al studied Chilean celiac
patients of Amerindian origin and found that genotype DQ8
predominate among this group. These results can possibly
be explained by the origins of the Chilean population,
formed by miscegenation of the Mapuche people with
Spaniards.12 In Brazil, the miscegenation is so great that it is
erroneous to identify genetic ancestry through physical
characteristics.23,24 Thus, in our population, it is impossible
to determine the composition of the group in terms of
Caucasian, Amerindian or black African origin.
Another finding from this group is that 79% of the
unaffected control families carried genotype DQ2 and/or
DQ8, which is one of the highest frequencies so far described
among first-degree relatives. Just like the genotypes DQ2
and DQ8, A1*0201, A1*05, B1*02 and B1*0302 alleles were
very frequently found among the first-degree relatives of the
patients. We raise the possibility that these data were
overestimated because of characteristics peculiar to this
group of controls. We believe that one of the biggest
limitations to this study is that, among the family controls,
there might be some patients. This would occur both because
of the characteristic that celiac disease may be manifested at
any time during life, which would put limits on evaluations
made at a single time, and because of the possibility of false
negative tTG findings. However, most studies on HLA
among first-degree relatives used designs similar to ours,
and found that no more than 59.5% of first-degree relatives
in Europe presented HLA DQ2 and DQ8.7,15
At present, there is no data on the distribution of HLA DQ
among the general population of Recife. Nevertheless, since
the frequencies of genetic markers among populations of
first-degree relatives reflect and amplify those among the
general population of which they form part, this allows us
to speculate that in our region, a large proportion of the
general population may carry these markers. One of the
theories that explain the differences in HLA between
different populations relates to negative selection of these
molecules that has occurred during human evolution.16 This
selection has been affected by the different antigen stimuli
to which each population has been exposed.25 In the case of
celiac disease, it depends primarily on gluten exposure, and
possibly also on other environmental factors.26
Recife is located in northeastern Brazil, a region that was
first peopled by Amerindian tribes, like the remainder of the
Americas. These tribes came from places where there was
no wheat-growing culture (peoples who came from Asia,
arriving here via the Bering Strait).27 Furthermore, differing
from Europe and the Middle East (the region around the
Fertile Crescent), where gluten has been consumed for more
than 10,000 years, this food only came to the Americas with
the European colonizers 500 years ago.26,28 Consequently, in
our region, there has been less time for negative selection of
Table 2 - Frequencies of genotypes DQ2 and DQ8 in
patients and control relatives.
HLA
Patients (%) Controls (%)
x2 pn (%) CI n (%) CI
Absent 5 (6.8) 2.5 – 15.9 27 (21.4) 14.8 – 29.8 7.28 0.006*
DQ2 50 (68.5) 56.4 – 78.5 66 (52.4) 43.3 – 61.2 4.94 0.026*
DQ8 13 (17.8) 10.1 – 28.8 20 (15.9) 10.1 – 23.6 0.13 0.72
DQ2 + DQ8 5 (6.8) 2.5 – 15.9 13 (10.3) 5.8 – 17.3 0.68 0.41
Total 73 (100) - 126 (100) - - -
*p , 0.05
Table 3 - Characteristics of the patients without HLA DQ2 or DQ8, with regard to sex, age, diagnostic symptoms and
alleles present in genotyping.
Patient Sex Age Signs and symptoms Alleles
1 F 3 years Diarrhea, abdominal pain, abdominal distension and malnutrition B1*02
2 F 8 years Diarrhea and weight loss B1*02
3 F 14 years Constipation, abdominal distension, abdominal pain, ulcers and asthenia B1*02
4 M 22 months Diarrhea, vomiting, abdominal distension and malnutrition B1*02 A1*0201
5 F 2 years Diarrhea, abdominal pain, abdominal distension and malnutrition Negative {
{For the four alleles investigated (A1*0201, A1*05, B1*02 and B1*0203)
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these genes, thereby leaving their frequencies relatively high
in this population.
Another finding from the present study was that five out
(6,8%) of the 73 celiac patients presented neither DQ2 nor
DQ8, although four of them had at least the allele B1*02.
Among these patients, only one did not have the classic
form of celiac disease, but this patient presented consider-
able gastrointestinal symptoms. These findings are concor-
dant with several previous studies in which it was demon-
strated that just one of the alleles A1*05 or B1*02, coding for
half of the DQ2 heterodimer molecule would confer a
predisposition towards triggering celiac disease.2,5,21
In our study, we found the A1*0201 allele in nine patients:
one of them was negative for DQ2 and DQ8 but had the
allele B1*02. These findings are concordant with European
data. In a multicenter study conducted in Europe in 2002, 61
out of the 1008 celiac patients studied did not present DQ2
and DQ8 genotypes. Thirty-four out of the 61 patients
presented the gene A1*0201 in association with B1*02, only
four were characterized non-DQ2 and/or DQ8 haplo-
types.21 It has been hypothesized that the genotype
A1*0201-B1*0201 is capable of coding for a molecule of
DQ2 with lower affinity for gliadin. The patient who did not
present any of the alleles investigated was diagnosed in
accordance with the criteria of ESPGHAN, with classic
symptoms, positive serological tests and signs of villous
atrophy from the biopsy. This patient underwent HLA
genotyping repeated three times in blind with the Dynal all
Set SSP kit and resulted HLA DQA1*01.
We hypothesize that in the subjects analyzed in our study
the genotypes DQ2 and DQ8 conferred vulnerability
towards the development of celiac disease. However, the
distribution of the frequencies of the genotypes DQ2 and
DQ8 were different from distributions found in European
populations. The distribution was closer to what has been
found in other studies conducted in the Americas. The high
frequencies of the HLA genotypes DQ2 and DQ8 found in
first-degree relatives would make it difficult to use these
HLA genotypes for routinely diagnosing celiac disease in
this specific group. In the future, it will be necessary to
investigate the HLA genotypes DQ2 and DQ8 in the general
population of Recife, in order to achieve better under-
standing of these markers in our region.
CONCLUSION
Although the genotypes DQ2 and DQ8 were presents in
the main of the celiac patients in Recife, northeastern Brazil,
the distribution of these genotypes was different from what
had been found in European population. The quite high
frequencies of the HLA genotypes DQ2 and DQ8 found in
first-degree relatives would make it difficult to use these
HLA genotypes for routinely diagnosing celiac disease in
this group.
This study was funded by the Brazilian National Counsel
of Technological and Scientific Development (CNPq) (Case
No. 475120 /2006-1).
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